The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
about
Oral tapentadol for cancer painOral tapentadol for cancer painOptimizing pain management to facilitate Enhanced Recovery After Surgery pathways.Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patientsDezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibitionEfficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.The present and future of opioid analgesics in small animal practice.Comparative metabolism of tramadol and tapentadol: a toxicological perspective.Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.Latin-American guidelines for opioid use in chronic nononcologic pain.Effect of electromagnetic field on cyclic adenosine monophosphate (cAMP) in a human mu-opioid receptor cell model.Review of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.Effectiveness of tapentadol prolonged release for the management of painful mucositis in head and neck cancers during intensity modulated radiation therapy.Is there a role for opioids in the treatment of fibromyalgia?Considering tapentadol as a first-line analgesic: 14 questions.Does 'Strong Analgesic' Equal 'Strong Opioid'? Tapentadol and the Concept of 'µ-Load'Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study
P2860
Q24186978-14401317-A3CD-4309-9CA7-48D51C18B7E3Q24187018-2ABBFB34-783C-4B9E-8A81-E0E496008242Q30369656-1B8AFAEE-02F5-4480-9E7C-6533E86E1BBDQ31128284-5A26DD54-2E3D-464E-AF1D-044EAE739F77Q34783638-8D328B9C-2102-449C-AEE9-03B5194C4DD3Q37661067-46049D48-97AE-4278-8939-6E96DBE36FD2Q38767585-454593E7-BDF2-4272-8957-BE236FA833AEQ38789121-0B910A2F-2797-4430-8BB5-ED0E5E2B0444Q38942405-27CBCB56-003A-4905-9750-87911A63CF3EQ39155270-2C6BA896-9741-4692-B2D9-309023A4C44FQ39160076-D1193946-0E9E-4762-8702-3F302F8692FFQ44330705-51FB4B6A-6AA0-4B87-9CF0-7D53214F4822Q47261672-6E92B098-AF7F-4908-8597-C02F324E69B1Q47834525-CB3A895D-8369-44F5-AE0C-4E572C6C1BAEQ53053272-C6C9C824-9E08-4DC6-8207-A402B2911F13Q53339459-3E15D1EE-F006-45E4-B871-EEF8E97C1271Q58749196-00EBDD07-F8F8-496C-A610-D9F08E25F99CQ58912037-DF9F4382-97C2-4CF0-939F-DA9DCEE4FD2D
P2860
The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The mu-opioid receptor agonist ...... gesia: the case of tapentadol.
@en
type
label
The mu-opioid receptor agonist ...... gesia: the case of tapentadol.
@en
prefLabel
The mu-opioid receptor agonist ...... gesia: the case of tapentadol.
@en
P2093
P2860
P1433
P1476
The mu-opioid receptor agonist ...... gesia: the case of tapentadol.
@en
P2093
Babette Y Kögel
Thomas Christoph
Thomas M Tzschentke
P2860
P2888
P304
P356
10.1007/S40263-014-0151-9
P577
2014-04-01T00:00:00Z